<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191129045542N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-07-17</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Comparative Effectiveness of the Customized poly-propylene Semi-rigid Insole and Prefabricated SiliconeHeel Pad in Pain Reduction and Functional Improvement of Patients with Plantar Fasciitis</public_title>
      <acronym></acronym>
      <scientific_title>Comparative Effectiveness of the Customized poly-propylene Semi-rigid Insole and Prefabricated Silicone Heel Pad in Pain Reduction and Functional Improvement of Patients with Plantar Fasciitis, A Clinical Trial Study.</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-08-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>54</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/64749</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: This research is a clinical trial study. Using the formula for comparing the mean in community with alpha 0.05 and
the ability (power) of 99% (1-beta:99%) as well as using the result of the same article (Baldassin et al), the sample size was calculated as 22 patients for each group. Taking into account the 20% drop, 27 patients for each group were
.determined as the final sample size.
Patients will be randomly allocated in to two groups by Block Randomization Assignment and Double blind
methods. We will describe the mechanism of the disease, various approaches of treatment, prognosis and our study
process as well as case selection for each patient.
). After the eligibility is determined, all subjects will be evaluated by one of the colleagues who will obtain baseline
characteristic data of the participants including age, sex, weight, duration of symptoms, history of analgesic
consumption. He/she will train stretching exercise of the plantar fascia and calf muscles as well as ask the items of both
questionnaires.  He/she will not know the type of orthoses prescribed for each patient. If both heels are painful,
only the data from the most symptomatic foot will be analyzed. If the pain severity is similar in both feet, only the
right foot will be evaluated. All patients will be advised to test the foot orthoses on
their footwear. If a participant complained of discomfort, he/she will be advised to use the orthosis for a minimum of one
week. If the orthosis still bothers the participant, he/she will be advised to return to our clinic (center of Orthosis and
Prosthesis in Shahid Chamran Hospital) for further evaluation. For improvement of blinding
method, both orthoses will be received by patients in our clinic. All insoles will tried to be made as similar as possible
in terms of materials. Each participant
will be advised not to show his/her orthosis to the questioner who will apply the scales. Each patient in both groups
should perform stretching exercises for plantar fascia and calf muscles with 5-10 times repetition in 3 sets per day which will be trained by one of the colleagues in the first visit.
.Descriptive Statistics: To describe quantitative variables, mean +_ standard deviation and 95% confidence interval
as well as to describe qualitative variables, frequency and frequency percentage will be used.
Inferential statistics: Independent sample t-test (nonparametric equivalent: Mann-Whitney test) which will be used
to compare the two groups in each time and also repeated measurement test (nonparametric equivalent: Friedman
test) will be used to check the comparison of times in each group.
Relationship between qualitative demographic variables such as gender and VAS, FFI scores through Independent
sample t-test (Mann-Whitney test) and the relationships of quantitative variables such as age, symptom duration and
weight with VAS and FFI scores will be determined by the Pearson correlation coefficient (nonparametric
equivalent: Spearman).
.SPSS25 will be used to analyze the data and the significance level in each of the tests is 0.05, Blinding description: Patients will be randomly allocated in to two groups by Block Randomization Assignment and Double blind
methods. We will describe the mechanism of the disease, various approaches of treatment, prognosis and our study
process and case selection for each patient. After the eligibility is determined, all subjects will be evaluated by one of the colleagues who will obtain baseline
characteristic data of the participants including age, sex, weight, duration of symptoms and history of analgesic
consumption. He/she will train stretching exercise of the plantar fascia and calf muscles as well as ask the items of both
questionnaires. He/she will not know the type of orthoses prescribed for each patient. If both heels are painful,
only the data from the most symptomatic foot will be analyzed. If the pain severity is similar in both feet, only the
right foot will be evaluated. The colleagues who provide the services in all steps of the project as well as analyzers will be blinded. For improvement of blinding
method, both orthoses will be received by patients in our clinic. All insoles will tried be made as similar as possible
in terms of materials. Each participant
will be advised not to show his/her orthosis to the questioner who will apply the scales. Each patient in both groups
should perform stretching exercises for plantar fascia and calf muscles with 5-10 times repetition in 3 sets per day which will be trained by one of the colleagues in the first visit.</study_design>
      <phase>2</phase>
      <hc_freetext>plantar fasciitis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: prefabricated silicone heel pad. Intervention 2: Intervention group: customized semi rigid polypropylene insole.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>No - There is not a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for not sharing IPD is No need</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Leila Sadat Mohamadi Jahromi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand street</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0098</zip>
        <telephone>+98 937 535 1951</telephone>
        <email>mohamadil.2668@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Leila Sadat Mohamadi JahromiS</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Zand street,  Faqihi hospital</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>0098</zip>
        <telephone>009836486064</telephone>
        <email>mohamadil.2668@gmail.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>- Sharp, shooting or localized pain in the sole of the foot for at least one month- 18 year-old patients or older.- Tenderness along the posteromedail aspect of the longitudinal arch or medial calcaneal tubercle.- Start-up pain in the morning with ambulation.- Decrease pain after walking</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>- Any lower extremity injuries including foot and ankle within 6 months.- Stress fracture- Receiving plantar steroid injection within 3 months.- Use of nonsteroidal anti-inflammatory medications within the previous one week.- Use of custom foot orthotics previously.- Other painful foot condition such as bunion, corn, or ingrown toe nail.- Any other lower extremity neuromuscular conditions such as active radiculopathy- Non-ambulatory, non-communicative.-Unable to complete the interview .- Spasticity due to a neurologic disorder.-Previous foot surgery.- Congenital defects of the lower extremity..- Diabetic mellitus</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M72.2</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Plantar fascial fibromatosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: prefabricated silicone heel pad</i_keyword>
      <i_keyword>Intervention group: customized semi rigid polypropylene insole</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain reduction and foot functional improvement. Timepoint: Before, 3 and 12 weeks after treatment. Method of measurement: Visual Analog Scale, Foot Function Index.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-05-23</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>ZAND Shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
